357 related articles for article (PubMed ID: 31541575)
1. Treatment of latent TB Infection and the risk of tuberculosis after solid organ transplantation: Comprehensive review.
Abad CLR; Deziel PJ; Razonable RR
Transpl Infect Dis; 2019 Dec; 21(6):e13178. PubMed ID: 31541575
[TBL] [Abstract][Full Text] [Related]
2. Fluoroquinolones for the treatment of latent
Silva JT; San-Juan R; Fernández-Ruiz M; Aguado JM
World J Gastroenterol; 2019 Jul; 25(26):3291-3298. PubMed ID: 31341356
[TBL] [Abstract][Full Text] [Related]
3. Clinical features and outcomes of tuberculosis in solid organ transplant recipients.
Bodro M; Sabé N; Santín M; Cruzado JM; Lladó L; González-Costello J; Carratalà J
Transplant Proc; 2012 Nov; 44(9):2686-9. PubMed ID: 23146494
[TBL] [Abstract][Full Text] [Related]
4. Outcome of latent tuberculosis infection in solid organ transplant recipients over a 10-year period.
Sidhu A; Verma G; Humar A; Kumar D
Transplantation; 2014 Sep; 98(6):671-5. PubMed ID: 24825525
[TBL] [Abstract][Full Text] [Related]
5. Positivity rate of interferon-γ release assays for estimating the prevalence of latent tuberculosis infection in renal transplant recipients in Japan.
Igari H; Akutsu N; Ishikawa S; Aoyama H; Otsuki K; Hasegawa M; Maruyama M; Tsuyuzaki M; Suzuki K; Saigo K
J Infect Chemother; 2019 Jul; 25(7):537-542. PubMed ID: 30905632
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.
Pease C; Hutton B; Yazdi F; Wolfe D; Hamel C; Barbeau P; Skidmore B; Alvarez GG
Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):557-566. PubMed ID: 29573031
[TBL] [Abstract][Full Text] [Related]
7. Mycobacterium tuberculosis in solid organ transplant donors and recipients.
Malinis M; Koff A
Curr Opin Organ Transplant; 2021 Aug; 26(4):432-439. PubMed ID: 34074939
[TBL] [Abstract][Full Text] [Related]
8. Prevention and treatment of tuberculosis in solid organ transplant recipients.
Abad CL; Razonable RR
Expert Rev Anti Infect Ther; 2020 Jan; 18(1):63-73. PubMed ID: 31826668
[No Abstract] [Full Text] [Related]
9. Mycobacterium tuberculosis infection in transplant recipients: early diagnosis and treatment of resistant tuberculosis.
Holty JE; Sista RR
Curr Opin Organ Transplant; 2009 Dec; 14(6):613-8. PubMed ID: 19741533
[TBL] [Abstract][Full Text] [Related]
10. Mycobacterium tuberculosis after solid organ transplantation: A review of more than 2000 cases.
Abad CLR; Razonable RR
Clin Transplant; 2018 Jun; 32(6):e13259. PubMed ID: 29656530
[TBL] [Abstract][Full Text] [Related]
11. Isoniazid prophylaxis in liver transplant recipient with latent tuberculosis: Is it harmful for transplanted liver?
Ghayumi SMA; Shamsaeefar A; Motazedian N; Mashhadiagha A; Sayadi M; Nikeghbalian S; Malekhosseini SA
Transpl Infect Dis; 2022 Aug; 24(4):e13849. PubMed ID: 35579604
[TBL] [Abstract][Full Text] [Related]
12. Treating tuberculosis in solid organ transplant recipients.
Sun HY
Curr Opin Infect Dis; 2014 Dec; 27(6):501-5. PubMed ID: 25211360
[TBL] [Abstract][Full Text] [Related]
13. Donor derived Mycobacterium tuberculosis infection after solid-organ transplantation: A comprehensive review.
Abad CLR; Razonable RR
Transpl Infect Dis; 2018 Oct; 20(5):e12971. PubMed ID: 30055041
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics, risk factors, and outcome of tuberculosis in kidney transplant recipients: A multicentric case-control study in a low-endemic area.
Gras J; De Castro N; Montlahuc C; Champion L; Scemla A; Matignon M; Lachâtre M; Raskine L; Grall N; Peraldi MN; Molina JM
Transpl Infect Dis; 2018 Oct; 20(5):e12943. PubMed ID: 29890021
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy.
Ramos GP; Stroh G; Al-Bawardy B; Faubion WA; Papadakis KA; Escalante P
Inflamm Bowel Dis; 2018 Sep; 24(10):2272-2277. PubMed ID: 29718223
[TBL] [Abstract][Full Text] [Related]
16. Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates.
de Castilla DL; Rakita RM; Spitters CE; Narita M; Jain R; Limaye AP
Transplantation; 2014 Jan; 97(2):206-11. PubMed ID: 24142036
[TBL] [Abstract][Full Text] [Related]
17. The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection.
Bliven EE; Podewils LJ
Int J Tuberc Lung Dis; 2009 Sep; 13(9):1054-60. PubMed ID: 19723392
[TBL] [Abstract][Full Text] [Related]
18. Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital.
Chung SJ; Lee H; Koo GW; Min JH; Yeo Y; Park DW; Park TS; Moon JY; Kim SH; Kim TH; Sohn JW; Yoon HJ
Sci Rep; 2020 Apr; 10(1):6462. PubMed ID: 32296096
[TBL] [Abstract][Full Text] [Related]
19. Mycobacterial infections in solid organ transplant recipients.
Meije Y; Piersimoni C; Torre-Cisneros J; Dilektasli AG; Aguado JM;
Clin Microbiol Infect; 2014 Sep; 20 Suppl 7():89-101. PubMed ID: 24707957
[TBL] [Abstract][Full Text] [Related]
20. Treatment guidelines for latent tuberculosis infection.
;
Kekkaku; 2014 Jan; 89(1):21-37. PubMed ID: 24654427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
